Compare ARKO & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | FTRE |
|---|---|---|
| Founded | 1970 | 1996 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 737.0M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | ARKO | FTRE |
|---|---|---|
| Price | $7.47 | $13.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.50 | ★ $14.06 |
| AVG Volume (30 Days) | 814.0K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | $3.09 |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $3.71 | $3.97 |
| 52 Week High | $7.50 | $18.67 |
| Indicator | ARKO | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 73.28 | 55.18 |
| Support Level | $4.80 | $8.85 |
| Resistance Level | N/A | $18.26 |
| Average True Range (ATR) | 0.30 | 0.78 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 99.59 | 9.69 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.